Oklahoma City, OKNCT05898399Now EnrollingIRB Ready

Breast Cancer Clinical Trial in Oklahoma City, OK

Access cutting-edge breast cancer treatment through this phase 1/2 clinical trial at a research site in Oklahoma City. Study-provided care at no cost to qualified participants.

Sponsored by Artios Pharma Ltd

Quick Self-Assessment

See if you qualify for this Oklahoma City location

Preparing your pre-screening questions…

Expert Care in Oklahoma City

Access breast cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related breast cancer treatment provided free

Apply for This Oklahoma City Location

Check if you qualify for this breast cancer clinical trial in Oklahoma City, OK

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Oklahoma City

    Convenient for OK residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Oklahoma City site if eligible
  4. 4Begin participation

About This Breast Cancer Study in Oklahoma City

This interventional study will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ART6043 as monotherapy or in combination with Olaparib or Niraparib.

Sponsor: Artios Pharma Ltd

Who Can Participate

Inclusion Criteria

Patients who have discontinued all previous chemotherapeutic agents, non-hormonal targeted therapy, or investigational drugs for at least 21 days or 5 half-lives (not including palliative radiotherapy at focal sites), whichever is shorter. Endocrine and hormonal therapies for the treatment of cancer must have been discontinued (unless for the treatment of Prostate Cancer) at least 7 days before receiving study medication. Palliative radiotherapy must have completed prior to start of study treatment.
Resolution of all toxicities of prior therapy or surgical procedures.
Performance status of 0-2 on the Eastern Cooperative Oncology Group (ECOG) scale.
Have adequate organ function.
Patients of childbearing potential and patients with partners of childbearing potential are required to use highly effective contraception.
Have an estimated life expectancy of ≥12 weeks, in the judgment of the investigator. Inclusion Criteria specific to Part A1 (ART6043 as Monotherapy) • Advanced or metastatic cancer. Tumors with genetic lesions known to cause loss of function of known DDR genes based on available pre-existing testing are encouraged. Inclusion criteria specific to Part A2 (ART6043 in combination with olaparib)
Advanced or metastatic cancer with genetic lesions known to cause loss of function of known DDR genes based on available, pre-existing testing.
Patients for whom a PARPi is an appropriate treatment option. Patients may have received prior treatment with a PARPi. Inclusion criteria specific to Part B (ART6043 in combination with olaparib or olaparib alone)
Histologically or cytologically confirmed HER2-ve locally advanced or metastatic carcinoma of the breast.
Documentation of a deleterious or suspected deleterious gBRCA mutation.
Previously treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting unless medically contraindicated.
Prior treatment with a taxane in the neoadjuvant, adjuvant, locally advanced, or metastatic setting unless medically contraindicated.
Patients must have received no or ≤1 month of prior treatment with a PARPi.

Exclusion Criteria

Patients who are pregnant.
Patients with Myelodysplastic syndrome (MDS)/Acute myeloid leukemia (AML) or with features suggestive of MDS/AML.
Have ongoing interstitial lung disease or pneumonitis.
Have any major gastrointestinal issues that could impact absorption of ART6043 or olaparib.
Patients with brain metastases (patients with treated brain metastases could be eligible if follow-up brain imaging after central nervous system-directed therapy shows no evidence of progression).
Have received a live vaccine within 30 days before the first dose of study treatment.
Recent major surgery within 4 weeks prior to entry into the study.
Have a significant bleeding disorder or vasculitis or had a Grade ≥3 bleeding episode within 12 weeks prior to enrollment.
Have a history of allergy or hypersensitivity to study drug components. Exclusion criteria specific to Part B
First-line locally advanced and/or metastatic breast cancer with no prior adjuvant chemotherapy.
Inflammatory breast cancer.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Oklahoma City?

Yes, this clinical trial (NCT05898399) has an active research site in Oklahoma City, OK that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Breast Cancer Treatment Options in Oklahoma City, OK

If you're searching for breast cancer treatment options in Oklahoma City, OK, this clinical trial (NCT05898399) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Oklahoma City research site is actively enrolling participants for this phase 1/2 clinical trial. You'll receive care from experienced breast cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all breast cancer clinical trials near you to find additional studies recruiting in your area.

More Breast Cancer Trials in Oklahoma City, OK

See all breast cancer clinical trials recruiting in Oklahoma City — not just this study.

Browse Breast Cancer Trials in Oklahoma City →

Browse More Trials by Condition

Breast Cancer TrialsTriple Negative Breast Cancer TrialsAnkylosing Spondylitis TrialsAll Conditions →

Ready to Join in Oklahoma City?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Oklahoma City, OK